Company intelligence / Profile preview

Newling Pharmaceutical

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Newling Pharmaceutical is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule therapeutics for cancer and autoimmune diseases. The company leverages a proprietary platform specializing in targeting protein-protein interactions (PPIs) and cyclin-dependent kinases (CDKs) to address unmet medical needs. Its lead program, NLP-21, is a highly selective CDK9 inhibitor currently undergoing clinical evaluation for various malignancies. Newling operates primarily out of Shanghai and Suzhou, China, maintaining a robust pipeline of candidates targeting cell cycle regulation and transcriptional control.

Therapeutic areas: HematologyOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Newling Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Newling Pharmaceutical.

Explore the full profile